

Contents lists available at [SciVerse ScienceDirect](http://SciVerse.ScienceDirect.com)

Developmental Biology

journal homepage: www.elsevier.com/locate/developmentalbiology

Paladin is an antiphosphatase that regulates neural crest cell formation and migration

Julaine Roffers-Agarwal, Karla J. Hutt¹, Laura S. Gammill^{*}

Department of Genetics, Cell Biology and Development, 6-160 Jackson Hall, 321 Church Street SE, University of Minnesota, Minneapolis, MN 55455, USA

ARTICLE INFO

Article history:

Received 24 March 2012

Received in revised form

5 August 2012

Accepted 15 August 2012

Available online 25 August 2012

Keywords:

Neural crest

Phosphorylation

Migration

ABSTRACT

Although a network of transcription factors that specifies neural crest identity in the ectoderm has been defined, expression of neural crest transcription factors does not guarantee eventual migration as a neural crest cell. While much work has gone into determining regulatory relationships within the transcription factor network, the ability of protein modifications like phosphorylation to modulate the function of neural crest regulatory factors and determine when and where they are active also has crucial implications. Paladin, which was previously classified as a phosphatase based on sequence similarity, is expressed in chick neural crest precursors and is maintained throughout their epithelial to mesenchymal transition and migration. Loss of Paladin delays the expression of transcription factors *Snail2* and *Sox10* in premigratory neural crest cells, but does not affect accumulation of *FoxD3*, *Cad6B* or *RhoB*, indicating that Paladin differentially modulates the expression of genes previously thought to be coregulated within the neural crest gene regulatory network. Both gain and loss of Paladin function result in disrupted neural crest migration, reinforcing the importance of precisely regulated phosphorylation for neural crest migration. Mutation of critical, catalytic cysteine residues within Paladin's predicted phosphatase active site motifs did not abolish the function of Paladin in the neural crest. Collectively, these data indicate that Paladin is an antiphosphatase that modulates the activity of specific neural crest regulatory factors during neural crest development. Our work identifies a novel regulator of phosphorylation status that provides an additional layer of regulation in the neural crest.

© 2012 Elsevier Inc. All rights reserved.

Introduction

Neural crest cells are a multipotent, migratory cell type that is unique to vertebrate embryos. Neural crest precursors originate as epithelial cells within the dorsal neural tube, then undergo an epithelial to mesenchymal transition and delaminate from the neural tube. Once motile, neural crest cells migrate to the periphery and eventually differentiate into a variety of cell types, including neurons and glia of the peripheral nervous system, craniofacial bone and melanocytes (LeDouarin and Kalcheim, 1999).

While a gene regulatory network (GRN) of transcription factors that regulate neural crest specification has been established (Betancur et al., 2010; Sauka-Spengler and Bronner-Fraser, 2008), cells of the dorsal neural tube are not uniquely fated to give rise to neural crest cells (Collazo et al., 1993; Selleck and Bronner-Fraser, 1995). In particular, expression of neural crest transcription factors does not guarantee that a cell will migrate

(Chizhikov and Millen, 2004b; Duband, 2006; Linker et al., 2000). For example, dorsal neural tube cells co-express *Snail2*, a neural crest marker, and *Lmx1a*, a roof plate marker, and become either cell type (Chizhikov and Millen, 2004a). Because expression of transcription factors that specify neural crest cell identity does not ensure neural crest development, we postulate that modulation of protein activity provides an additional layer of control during neural crest development.

Phosphorylation is a well-established mechanism for regulating protein activity. A phosphate group is added to a serine, threonine or tyrosine residue within the targeted protein by a kinase, and the process is reversible through the activity of a phosphatase (Sefton and Shenolikar, 2001). Phosphorylation status is also regulated by a third class of proteins, the antiphosphatases, sometimes referred to as pseudophosphatases.

Antiphosphatases contain incomplete or divergent inactive phosphatase domains and bind to phosphorylated residues on target proteins to protect them from dephosphorylation (Cui et al., 1998; Gingras et al., 2009; Wishart and Dixon, 1998). While kinase and phosphatase inhibitor treatments show that phosphorylation in general regulates neural crest adhesion and migration (Brennan et al., 1999; Minichiello et al., 1999; Monier-Gavelle and Duband, 1995; Newgreen and Minichiello, 1995), only recently

^{*} Corresponding author. Fax: +1 612 626 5652.

E-mail address: gammil001@umn.edu (L.S. Gammill).

¹ Current address: Prince Henry's Institute of Medical Research, Level 4, Block E, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia.

have specific regulators of phosphorylation status been identified. A growing list of kinases active in neural crest cells (for example Banerjee et al., 2011; Jin et al., 2012; Murphy et al., 2011; Ossipova and Sokol, 2011) reinforces the idea that phosphorylation is important for neural crest development. Meanwhile, mutation of the phosphatase Shp2 was recently shown to cause abnormalities in neural crest derivatives (Nakamura et al., 2009; Stewart et al., 2010) while inhibition of PP2A phosphatase activity results in increased cranial neural crest migration (Latta and Golding, 2012). While target protein phosphorylation status can determine biological activity, for example phosphorylation of the neural crest transcription factor Twist affects binding partner choice and transcriptional outcome (Firulli and Conway, 2008), a neural crest antiphosphatase that can sustain target phosphorylation has never been described.

Paladin (Pald) is a protein that contains two phosphotyrosine phosphatase consensus active site motifs but lacks other domains characteristic of phosphatases. Found only in vertebrates, Pald was first identified in a large-scale cDNA sequencing project (Nagase et al., 1999) and was subsequently identified in a screen for genes upregulated as a consequence of neural crest induction (Adams et al., 2008; Gammill and Bronner-Fraser, 2002). Recent work has shown that Pald inhibits insulin-stimulated phosphorylation of AKT; however, in vitro assays have failed to detect phosphatase activity for Pald (Huang et al., 2009). As no in vivo functional assays have assessed the importance of Pald's phosphatase domains, it is unclear whether to categorize Pald as a phosphatase or antiphosphatase (Alonso et al., 2004).

We have examined the role that Pald plays in chick neural crest development. *Pald* is expressed in premigratory and migratory neural crest cells, consistent with a role in the neural crest. Loss of Pald results in reduced expression of some neural crest transcription factors, but not others, indicating Pald differentially regulates pathways in the neural crest GRN. Later in development, both gain and loss of Pald result in disrupted neural crest migration, indicating Pald levels are strictly regulated during neural crest migration. Additionally, mutation of critical cysteines in Pald's putative phosphatase active site motifs does not abolish Pald function. As these mutations should eliminate Pald activity if it is a phosphatase, and because Pald does not exhibit phosphatase activity in vitro (Huang et al., 2009), we propose that Pald is an antiphosphatase that regulates the phosphorylation and activity of target proteins during neural crest development.

Materials and methods

Chicken embryo culture

Fertile chicken embryos were obtained from local sources and incubated in a humidified incubator at 37–38 °C (G.Q.F. Manufacturing; Savannah, GA). Embryos were staged according to Hamburger and Hamilton (1951) or by counting somite pairs.

Morpholinos and DNA constructs

FITC- or lissamine-tagged morpholinos (MOs) were obtained from GeneTools, LLC (Philmouth, OR) with the following sequences: translation blocking cPald MO TGCACGCTCTCAAAGCGGAGGCTG; 5 bp mismatch control mmcPald MO TGgACcTCTgAAAGcCGGAcGCTG; splice blocking spcPald MO CAACAAGCAGCAATGCCAACCTGCA; 5 bp mismatch control mmSPcPald MO CAAGaAcCAcCAATcC-CAACCTcCA. For overexpression, full-length Pald was subcloned using standard methods into pMES (Swartz et al., 2001) with GFP replaced with mcherry (pMES-mcherry) using PCR driven overlap extension (Heckman and Pease, 2007). Phosphatase active site mutations were

made using a QuikChange II Site-Directed Mutagenesis Kit (Agilent; Santa Clara, CA).

Electroporation

Embryos at HH stage 4–5 were electroporated with morpholino and DNA as previously described (Gammill and Krull, 2011). Morpholinos were used at 1.0 mM with or without DNA. DNA for overexpression was electroporated at 1–5 mg/ml as indicated along with 1.0 mM standard control MO. After electroporation, embryos were reincubated to the appropriate stages, fixed with 4% paraformaldehyde at RT for 1 h, and imaged using fluorescent microscopy. Embryos were screened for appropriately targeted, bright MO incorporation prior to analysis because the MO fluorescent tag often does not persist after in situ hybridization. Embryos were then dehydrated into methanol and stored at –20 °C for in situ hybridization or embedded immediately for sectioning.

In vitro translation

In vitro translation was performed using the FluoroTect GreenLys in vitro Translation labeling system and Rabbit Reticulocyte Lysate (Promega; Madison, WI) according to the manufacturer's instructions. Briefly, full length chick Paladin, including 44 bp of 5' UTR, was cloned from a chick embryo expression library (Gammill and Bronner-Fraser, 2002) and subcloned into CS2+myc (Turner and Weintraub, 1994). A construct containing a 5 base pair mismatch in the morpholino target sequence (mmcPald) was generated by PCR using primers containing the mismatch target site. mRNA for Pald or mmcPald was in vitro transcribed and used as template for in vitro translation. 0.5 mM or 1.0 mM cPald MO was added to selected samples. Reactions were run out on a 10% Tris–HCl SDS PAGE gel, and results visualized on an FLA-5000 imager (FujiFilm; Stamford, CT). Band intensity was measured and compared using Image Gauge software (FujiFilm).

RT-PCR

Electroporated embryos were incubated to 6–8 somites. MO targeted hemi-heads were dissected from these embryos and RNA was isolated using Trizol (Life Technologies; Grand Island, NY) and reverse transcribed using SuperScript III (Life Technologies; Grand Island, NY) according to manufacturer's instructions. cDNA was then used as template for PCR reactions using Choice Taq (Denville Scientific; Metuchen, NJ). No reverse transcriptase samples were used as negative controls. Primer sequences were as follows: Pald exon2 F-CCTGAGCATCCACTCCTTTC; Pald exon4 R-GCTGACCCATACCAACACC; GAPDH F-GGACACTTCAAGGGCACTGT; GAPDH R-TCTCCATGGTGGTGAAGACA.

In situ hybridization

Digoxigenin-labeled RNA probes were translated using the following constructs as templates: *Snail2* (Gammill and Bronner-Fraser, 2002); *Sox10* (Cheng et al., 2000); *FoxD3* (Kos et al., 2001); *Cad6B* (Gammill and Bronner-Fraser, 2002); *RhoB* (gift of Lisa Taneyhill); *Msx1* (clone ChEST900p21; Boardman et al., 2002); and *Sox2* (Uwanogho et al., 1995). In situ hybridization was performed as described previously (Wilkinson, 1992). Embryos were viewed in whole mount with a Zeiss Discovery V8 stereoscope and selected embryos were embedded and sectioned with a Leica CM1900 cryostat at 10–20 µm and imaged on a Zeiss Axiolmager A1.

Phenotype evaluation

Phenotype was evaluated at cranial axial levels well targeted with fluorescent MO signal. Effects on premigratory gene expression in whole mount were analyzed by comparing the relative intensity of in situ hybridization colorimetric signal on the targeted and untargeted sides of the embryo using the criteria shown in Fig. S1. In section images, the cross-sectional area of the expression domain on targeted and untargeted sides of the neural tube were compared in five sections of selected embryos using Image J (NIH). Effects on migration were scored by comparing the distance migrated on targeted and untargeted sides using the criteria shown in Fig. S1. Statistical analysis of phenotypic effects was performed using Fisher's exact test in R (R Development Core Team, 2011).

Immunostaining and cell counting

Embryos were infiltrated with 5% and 15% sucrose, embedded in gelatin, frozen in liquid nitrogen and sectioned with a Leica CM1900 cryostat at 10–20 μm . Sections were stained with anti-HNK-1 (ATCC; Manassas, VA), anti-cleaved caspase3 (Cell Signaling; Danvers, MA) or anti-phospho-Histone H3 (Millipore; Billerica, MA) followed by the appropriate secondary antibody (Cy2 anti-Mouse IgM or Cy5 anti-Rabbit, Jackson; West Grove, PA) as indicated. Slides were mounted with PermaFluor (Thermo Fisher Scientific; Waltham, MA) containing DAPI and viewed on either a Zeiss AxioImager A1 or a Zeiss CARV spinning disk confocal microscope. Images were adjusted in Photoshop (Adobe). Nuclei and dividing or dying cells were counted in the dorsal quarter of the cranial neural tube on both the targeted and untargeted sides of the embryo for at least five sections per embryo and statistics were performed in Excel (Microsoft).

Results

Chick Paladin is expressed in premigratory and migratory neural crest cells

In order to better understand early neural crest development, previous work identified 176 genes that are upregulated as neural crest cells are preparing to migrate (Adams et al., 2008; Gammill and Bronner-Fraser, 2002). One of these genes, Paladin (incorrectly identified as Palladin in Gammill and Bronner-Fraser, 2002), is annotated as a putative phosphatase and its expression profile remains unreported. Chick *Pald* was expressed in premigratory neural crest cells at 4 somites in cranial (Fig. 1B, open arrowhead) and trunk domains (Fig. 1D, open arrowhead) as well as along the basal surface of the neural tube (Fig. 1C and D, white arrows). This expression persisted in cranial and trunk premigratory neural crest precursors at 8 somites (Fig. 1G and H, arrowheads), indicating that *Pald* is expressed throughout premigratory neural crest development.

Both cranial and trunk neural crest cells maintained expression of *Pald* as they delaminated from the neural tube (Fig. 1K and M, closed arrowheads) and migrated away (Fig. 1F and J). *Pald* mRNA expressing cells outside of the neural tube (Fig. 1J, arrowhead) were confirmed as neural crest cells by costaining with HNK-1 (Fig. 1J', arrowhead). Expression of *Pald* was still apparent in migrating neural crest cells and their derivatives within the branchial arches at 30 somites (Fig. 1L, arrowheads). Additionally, *Pald* was expressed in otic placode and vesicle cells (Fig. 1C, E, G, and I, o) as well as nascent blood vessels (Fig. 1H, black arrows). Expression of *Pald* transcripts in neural crest cells at multiple

stages puts *Pald* in the right time and place to regulate neural crest development.

Paladin is required for premigratory expression of *Snail2* and *Sox10* but not other neural crest genes

We designed a translation blocking morpholino against chick *Pald* (c*Pald* MO) to examine the requirement for *Pald* during neural crest development. To test the ability of this morpholino to inhibit translation of *PALD* protein, we performed in vitro translation reactions. Inclusion of c*Pald* MO in the translation reaction resulted in a dose-dependent decrease in the amount of *PALD* produced (Fig. S2A). c*Pald* MO was ineffective when 5 base pairs of the morpholino target site were changed, indicating that c*Pald* MO is specific. We also utilized a second morpholino designed against the splice donor site of intron 3 (spc*Pald* MO). This morpholino altered *Pald* mRNA splicing when assessed using RT-PCR (Fig. S2B).

To determine whether *Pald* regulates neural crest development in chicken embryos, we electroporated the *Pald* MOs unilaterally into neural crest precursors at mid-gastrula, during neural crest specification (Basch et al., 2006; Gammill and Krull, 2011). Electroporated embryos were then analyzed for expression of *Snail2* by in situ hybridization in whole mount and transverse sections when neural crest cells were still in the neural tube. Electroporation of a morpholino with a 5 base pair mismatch (mmc*Pald* MO) did not affect premigratory expression of *Snail2* on the targeted side of embryos (Fig. 2A, asterisk; Fig. 2H, $n=18$). However, knock down of *Pald* using c*Pald* MO resulted in a consistent decrease in the expression of *Snail2* on the targeted side relative to the untargeted side of 68% of embryos analyzed (Fig. 2B, asterisk; Fig. 2H, $p=1.1 \times 10^{-3}$, $n=19$). A similar, but slightly stronger effect was observed in 87% of embryos electroporated with spc*Pald* MO (Fig. 2H, $p=1.1 \times 10^{-3}$, $n=15$). Thus, *Pald* is required for premigratory *Snail2* expression in the neural crest.

To assess whether *Pald* regulates neural crest cell specification generally or *Snail2* expression specifically, we examined premigratory expression of other neural crest cell markers. While effects on *Sox10* expression were subtle in whole mounts (Fig. 2C and D top), defects were apparent in sectioned embryos (Fig. 2C and D bottom). 44% of mmcspc*Pald* MO electroporated embryos displayed slightly decreased *Sox10* expression (Fig. 2C and H, $n=9$), indicating that the morpholino is at the upper limit of its effective- and specific-dose range (Moulton and Yan, 2008). Nevertheless, *Sox10* expression was slightly to moderately decreased in all embryos electroporated with spc*Pald* MO, with 44% exhibiting a moderate reduction (Fig. 2D and H, $p=8.5 \times 10^{-3}$, $n=9$). While both *Snail2* and *Sox10* are transcription factors regulating neural crest cell fate, a third transcription factor, *FoxD3*, was unaffected upon *Pald* knock down by either c*Pald* ($n=23$) or spc*Pald* ($n=14$) MO (Fig. 2E and I). Furthermore, two neural crest cell effector genes, *RhoB* (Fig. 2F and I) and the epithelial cadherin *Cad6B* (Fig. 2G and I), were normally expressed as well following *Pald* MO electroporation. Importantly, *Cad6B* was downregulated on time in *Pald*-deficient embryos (Fig. 2G). Notably, neural and dorsal neural tube makers were also expressed normally in *Pald* knock down embryos, revealing intact patterning of neural tube fates (Fig. S3). As in the case of *Snail2* expression, both MOs elicited similar phenotypes for all neural crest markers analyzed (Fig. 2H and I). These results indicate that *Pald* is required for expression of both *Snail2* and *Sox10*, but not for neural crest specification generally.

Initial reductions in *Snail2* and *Sox10* transcripts could have been caused by increased rates of cell death or decreased cell proliferation in neural crest cells. To examine this possibility, we electroporated embryos with mmcspc*Pald* MO or spc*Pald* MO and assessed cell proliferation and death markers in embryo sections at premigratory neural crest cell stages. Quantification of dying




Fig. 1. Paladin is expressed in premigratory and migratory neural crest cells. (A–D) Cranial (B and C), and trunk (D) premigratory neural crest cells (open arrowhead) express *Pald* mRNA at 4 somites (4 s). (E–M) At 8 s (E–H), 10 s (I–K), and 30 s (L and M), *Pald* expression persists in hindbrain (G) and trunk premigratory neural crest cells (H, open arrowheads) and is maintained during delamination and migration of midbrain (F, I, and J), hindbrain (K and L), and trunk neural crest cells (M; arrowheads). *Pald* expressing cells (J, arrowhead) are positive by immunofluorescence for the migratory neural crest marker HNK-1 (J', arrowhead), confirming their identification as neural crest cells. *Pald* is also expressed in the basal surface of the neural tube (white arrows), blood vessels (black arrows), and dermomyotome (asterisk). (A, E, and I) dorsal view; (L) dorsolateral view; (B–D, F–H, J, K, and M) transverse section at the level indicated in the accompanying whole mount. (I) Higher magnification view. Fg, foregut; nt, neural tube; o, otic placode.

and proliferating cells revealed that electroporation of neither mmspcPald MO nor spcPald MO altered rates of either cell death or proliferation in the dorsal neural tube (Fig. S4). Similar results were observed with cPald MO (data not shown). Thus Paladin does not appear to regulate cell proliferation or death but expression of particular neural crest genes specifically.

Neural crest migration is disrupted upon Paladin knock down

Because *Pald* was expressed throughout neural crest development (Fig. 1), we wanted to determine if Paladin was also required for neural crest migration. We again knocked down

Pald using unilateral morpholino electroporation at mid-gastrula, but instead let embryos develop to 8 to 11 somites. When cranial neural crest cells were visualized in these embryos by whole-mount HNK-1 immunofluorescence, we noted that migration of cPaldMO-electroporated neural crest cells was curtailed (Fig. 3A, arrowheads). To characterize this disruption, we performed *Sox10* in situ hybridization, as *Sox10* is a robust marker of neural crest cells throughout their emigration and active migration (Cheng et al., 2000), and because moderate levels of *Sox10* expression are retained in *Pald* knock down embryos (Fig. 2D). While a minority of mmspcPald MO, mmcPald MO, and standard control MO electroporated embryos exhibited slight migratory defects on




Fig. 2. *Pald* is required for premigratory expression of *Snail2* and *Sox10*. Embryos were unilaterally electroporated at HH stage 4–5 with mmcPald MO (A), cPald MO (B, E, F, and G), mmspcPald MO (C) or spcPald MO (D). After reincubation to 4–8 somites (s), in situ hybridization was performed to assess expression of *Snail2* (A and B), *Sox10* (C and D), *FoxD3* (E), *RhoB* (F), or *Cad6B* (G). (A–D) Representative examples of *Snail2* and *Sox10* expression inhibition following *Pald* knock down. *Snail2* expression is unaffected in embryos electroporated with mmcPald MO (A) but reduced on the side of the neural tube targeted with cPald MO (B). Likewise, *Sox10* expression is unaffected in embryos electroporated with mmspcPald MO (C) but reduced on the side of the neural tube targeted with spcPald MO (D). (E–G) Representative examples of neural crest regulators unaffected by *Pald* knock down. Expression of the transcription factor *FoxD3* (E) and neural crest effector genes *RhoB* (F) and *Cad6B* (G) is equivalent on cPaldMO targeted and untargeted sides of the neural tube. (H) Stacked bar graphs depicting the frequency and severity of *Snail2* and *Sox10* expression defects in embryos electroporated with cPald MO, spcPald MO, mmcPald MO, mmspcPald MO, or control (co) MO when assayed in whole mount (*Snail2*) or sections (*Sox10*). (I) Stacked bar graphs reveal the absence of *FoxD3*, *Cad6B*, and *RhoB* expression defects in nearly all embryos assayed. In (A–G), top row: dorsal views of in situ hybridization in left panel, fluorescent MO targeting in right panel; bottom row: transverse sections at the level of the midbrain. Note that the section shown is not necessarily from the wholemount embryo pictured. Asterisk, targeted side of the embryo.

the targeted side (Fig. 3B and F), electroporation of spcPald MO or cPald MO resulted in a slight to severe decrease in the distance migrated on the targeted side compared to the untargeted side in over 90% of embryos (Fig. 3C and F, spcPald MO $p=4.8 \times 10^{-4}$, cPald MO $p=6.3 \times 10^{-5}$). Together, these results indicate that *Pald* is required for proper neural crest migration.

As *Sox10* is expressed at relatively normal levels in *Pald* knock down embryos at migratory stages (compare Figs. 2D and 3C), we determined whether *Snail2* expression would also recover.

Interestingly, when cPaldMO electroporated embryos were processed by *Snail2* in situ hybridization at early migratory stages, elevated *Snail2* expression was apparent in the targeted neural fold (Fig. 3E and E', asterisk). Moreover, cPaldMO-targeted migratory neural crest cells expressed *Snail2* at levels equivalent to migratory neural crest cells on the untargeted side (Fig. 3E), and once again revealed that *Pald* is required for neural crest migration (Fig. 3F, $p=4.8 \times 10^{-3}$). As neural crest migration progressed, *Pald*-deficient neural crest cells appeared to “catch




Fig. 3. Loss of Pald impedes neural crest migration. Embryos were unilaterally electroporated at HH stage 4–5 with cPaldMO, mmPald MO, spcPald MO, or standard control MO (coMO) and reincubated to 8–11 somites (s). (A) Neural crest migration defects visualized by HNK-1 immunofluorescence following Pald knock down. cPald MO-targeted neural crest cells (red; arrowheads) do not migrate as far as HNK-1 positive neural crest cells (green) on the untargeted side. (B and C) A representative example of neural crest migration defects visualized by *Sox10* in situ hybridization following Pald knock down. While mmPald MO does not affect neural crest migration (B), spcPald MO-targeted neural crest cells' migration distance is reduced compared to the untargeted side (C). (D and E) A representative example of neural crest migration defects visualized by *Snail2* in situ hybridization following Pald knock down. While coMO does not affect neural crest migration (D), cPald MO-targeted neural crest cells' migration distance is reduced compared to the untargeted side. (E') transverse section at the level of the line indicated in E. (B–E) Dorsal views of in situ hybridization in left panel, fluorescent MO targeting in right panel. Asterisk, targeted side of the embryo. (F) Stacked bar graphs depicting the severity and frequency of migration impairment in embryos electroporated with cPald MO, spcPald MO, mmPald MO, or coMO and visualized by *Sox10* (left) or *Snail2* (right) in situ hybridization. Migration of neural crest cells is mildly disrupted by electroporation of mmPald MO, indicating that 1.0 mM spcPald MO is the upper limit of its effective and specific dose.

up" to the untargeted side regardless of the marker used (data not shown). These data suggest that absence of *Snail2* is not preventing neural crest migration, and that Pald is necessary to coordinate early migration rather than active migration into the periphery.

Excess Paladin impedes neural crest migration

Because loss of Pald disrupted neural crest migration, we next wanted to examine the effects of Pald excess. To achieve this,

we cloned chick Pald into the bicistronic expression construct pMES-mcherry. We electroporated pMES-Pald-mcherry DNA unilaterally into midgastrula stage embryos and assessed neural crest cell migration. FITC-tagged control morpholino was included in these electroporations because we find coelectroporation of morpholino along with DNA results in a higher efficiency of DNA transfection and FITC fluorescence is brighter than mcherry, allowing for more accurate detection of properly transfected embryos. Surprisingly, overexpression of Pald-mcherry at 5 mg/ml yielded a decrease in neural crest migration distance (Fig. 4B and E, $p=5.6 \times 10^{-5}$), similar to Pald knock down, whereas electroporation of pMES-mcherry alone did not affect migration (Fig. 4A and E). Importantly, the incidence and severity of Pald overexpression defects was dose-dependent (data not shown). Pald overexpression outside of the neural crest domain had no apparent effect, suggesting Pald can affect active neural crest signaling pathways, but cannot trigger their activation. These results indicate that both loss and gain of Pald function disrupt neural crest migration, and Pald modulates neural crest development but does not initiate it.

Mutation of Paladin's protein tyrosine phosphatase domains does not abolish Paladin function

While Paladin has been preliminarily classified as a protein tyrosine phosphatase (PTP), little has been done to characterize its biological function, likely because Pald does not exhibit phosphatase activity *in vitro* (Huang et al., 2009). To examine the activity of Pald, we assessed whether Pald's PTP motifs were essential for proper neural crest migration. Pald contains two core PTP active site signature motifs, CX₅R (Fig. 4D, Tonks, 2006), but no other phosphatase accessory domains. Because the conserved cysteine is critical for catalytic activity and phosphatase function as it transiently accepts the phosphate during catalysis (Guan and Dixon, 1991), we mutated both of Pald's putative active site cysteines (C285 and C648) to serines (Fig. 4D). With other phosphatases, this strategy abolishes phosphatase activity, resulting in proteins that still recognize their substrates but no longer dephosphorylate and release them; cysteine mutants are thus called substrate-trapping mutations (Milarski et al., 1993).




Fig. 4. Pald overexpression disrupts neural crest migration. Embryos were unilaterally electroporated at HH stage 4–5 with pMES-mcherry expression constructs mixed with 1.0 mM FITC-labeled standard control MO (coMO). The MO served as a lineage tracer and a carrier for the DNA. At 8–11 somites (s), embryos were harvested and neural crest cells visualized by *in situ* hybridization for *Sox10*. (A–C) Representative embryos showing inhibition of migration by Pald overexpression. Whereas neural crest migration is unaffected by pMES-mcherry electroporation (A), electroporation of Pald-mcherry (B) or C285/648S phosphatase domain mutant Pald (C) disrupts neural crest migration on the targeted side. Dorsal views of *in situ* hybridization in left panel, fluorescent MO in right panel. Asterisk, targeted side of the embryo. (D) Schematic of Pald sequence. Phosphotyrosine phosphatase sites in yellow, active site cysteine is mutated in both domains in C285/648S. (E) Stacked bar graphs depicting the severity and frequency of migration defects in embryos overexpressing either wildtype or phosphatase mutant Pald.




Fig. 5. Phosphatase domain catalytic cysteine residues are not essential for Paladin activity in neural crest cells. Embryos were unilaterally electroporated at HH stage 4–5 with spcPald MO mixed with pMES-mcherry vector DNA, pMES-Pald-mcherry or pMES-C285/648S-mcherry and reincubated. At 8–11 somites (s) embryos were harvested and neural crest cells visualized by in situ hybridization for *Sox10*. (A–C) Representative examples of spcPald MO rescue. While neural crest migration is disrupted upon unilateral coelectroporation of empty pMES-mcherry (A), neural crest cells migrate normally following coelectroporation of 5 mg/ml pMES-Pald-mcherry (B) or 5 mg/ml C285/648S-mcherry (C). Dorsal views of in situ hybridization in left panel, fluorescent MO in right panel. Asterisk, targeted side of the embryo. (D) Stacked bar graphs depicting the severity and frequency of migration defects in embryos coelectroporated with spcPald MO and wildtype or phosphatase mutant Pald.

We therefore reasoned that if Pald was a phosphatase, these mutations (C285/648S) would eliminate Pald function, whereas if Pald was an antiphosphatase, Pald activity would be retained. Like wildtype Pald, electroporation of C285/648S disrupted neural crest migration (Fig. 4C and E, $p=0.016$). The number of embryos affected by C285/648S overexpression was not significantly different compared to wildtype Pald overexpression (Fig. 4E, $p=0.31$), however, the phenotypic severity was decreased. These data suggest that the conserved cysteines within the Pald PTP catalytic domains are required for complete Pald activity in regulating neural crest migration. However, because the migration disrupting activity of Pald was still intact, the active sites are unlikely to confer phosphatase catalytic activity.

Paladin active site mutants rescue Paladin loss of function in neural crest cells

To fully assess the biological activity of Pald during neural crest development, we wanted to see if the C285/648S mutant protein could substitute for endogenous Pald. First, we needed to establish the ability of wildtype Pald to rescue spcPald MO electroporated embryos. We coelectroporated spcPald MO with varying amounts of Pald-mcherry DNA that is not targeted by either MO. While some rescue was observed at 3 and 4 mg/ml Pald-mcherry (data not shown), optimal rescue was observed at 5 mg/ml and further experiments were carried out at this

concentration (Fig. 5B and D). Knock down of Pald using spcPald MO once again disrupted neural crest migration by decreasing the distance migrated in almost 90% of embryos (Fig. 5A and D), whereas coelectroporation of spcPald MO with Pald-mcherry resulted in normal migration in about 50% of embryos (Fig. 5B and D, $p=0.039$). These data indicate that disrupted neural crest migration following spcPald MO electroporation is specifically due to loss of Pald function, as replacement with exogenously supplied Pald rescues this defect.

Next, to assess the importance of the putative active site cysteines, we examined the ability of C285/648S to rescue spcPald MO knock down. While overexpression of C285/648S suggested that these cysteine residues, which are critical for function of a phosphatase active site, are important for Pald function during neural crest migration, we do not know the mechanism by which overexpression prevents neural crest migration. Knocking down endogenous Pald with spcPald MO and rescuing with C285/648S provides a more direct test of the importance of the putative active site cysteines. Following coelectroporation of spcPald MO with C285/648S, about 50% of embryos exhibited normal neural crest migration (Fig. 5C and D, $p=0.031$). Although the proportion of embryos rescued by wildtype or C285/648S coelectroporation was similar and not significantly different (Fig. 5D; $p=0.76$), those embryos that were affected exhibited more severe phenotypes with C285/648S rescue than those rescued with wildtype Pald. These results indicate that while putative active site cysteine

residues are not essential for Pald function in the neural crest, these residues are necessary for maximal Pald activity during neural crest migration.

Discussion

The function of Pald, which was presumed to be a phosphatase, was unknown during embryogenesis. Here, we show that Pald is expressed in premigratory and migratory neural crest cells, and that this expression is maintained in later neural crest derivatives, suggesting that Pald plays a role throughout neural crest development. Pald knock down demonstrates that Pald affects premigratory *Snail2* and *Sox10* expression but not neural crest specification generally. Additionally, loss and gain of function analysis reveals that Pald regulates early neural crest migration. Finally, our mutational analysis reveals that protein tyrosine phosphatase active site cysteine residues are not essential for Pald activity, indicating that Pald is an antiphosphatase that binds and protects phosphorylated residues during neural crest migration.

Paladin differentially affects members of the neural crest gene regulatory network

Genes involved in the early stages of neural crest development have been characterized in multiple species and their regulatory interactions organized into a gene regulatory network (Betancur et al., 2010). The neural crest specification transcription factors *Snail2*, *Sox10*, and *FoxD3* are expressed in premigratory neural crest cells and downregulated at various points once migration commences. Two of these transcription factors, *Snail2* and *FoxD3*, were found to be activated by similar sets of genes, namely *Msx1* (Tribulo et al., 2003), *Pax3/7* (Sato et al., 2005), and *Hairy2* (Glavic et al., 2004; Wettstein et al., 1997). Interestingly, loss of Pald in premigratory neural crest cells results in differential effects on these genes with a disruption in *Snail2* expression (Fig. 2B and H) and no effect on *FoxD3* (Fig. 2E and I), indicating that these transcription factors have differential regulation that has not been appreciated by neural crest gene regulatory analysis to date. The third transcription factor, *Sox10*, is expressed at a slightly later stage in development than *Snail2* and *FoxD3* and its expression in premigratory neural crest cells is also disrupted by loss of Pald, though to a lesser extent than *Snail2* (Fig. 2D and H). These data indicate that Pald selectively impacts neural crest transcription factor expression.

One potential explanation for this differential effect on neural crest transcription factors is that Pald directly regulates *Snail2* expression. Interestingly, SNAIL2 is a highly unstable protein in neural crest cells (Vernon and LaBonne, 2006) and in cancer cells, Snail stability is influenced by phosphorylation (Zhou et al., 2004). Furthermore, Snail positively autoregulates its own expression (Fuse et al., 1996). Nevertheless, we were unable to detect an interaction between Pald and SNAIL2 using directed yeast-two hybrid (data not shown). This implies that Pald does not directly regulate *Snail2* expression by modulating SNAIL2's phosphorylation status, and instead that Pald modulates a protein that regulates *Snail2* but not *FoxD3* expression. Efforts to identify such a target of Pald are currently underway.

Examination of neural crest effector genes upon Pald knock down also revealed novel insights into previously characterized neural crest gene regulatory interactions. Cellular effectors of neural crest development act subsequent to neural crest transcription factor expression, promoting delamination and migration. RhoB activity is required for delamination from the neural tube (Liu and Jessell, 1998) and its expression was unaffected by Pald knock down (Fig. 2F and I). *Cad6b* is an epithelial cadherin whose expression is directly downregulated in cranial neural

crest cells by *Snail2* prior to delamination (Taneyhill et al., 2007). Interestingly, though *Snail2* expression is disrupted in premigratory neural crest cells, we did not observe a delay in the downregulation of *Cad6b* transcripts as we would have expected given their direct regulatory relationship (Fig. 2G and I). This unexpected result reveals that regulation of *Cad6b* expression can be uncoupled from *Snail2*, indicating that *Cad6b* transcriptional regulation is more complex than currently appreciated and warrants additional characterization. Altogether, our data reveal that Pald is required for expression of specific neural crest regulatory genes, but not neural crest specification in general.

Paladin regulates but is not essential for neural crest migration

Our data indicate that either loss or gain of Pald disrupts neural crest migration. Analysis during early stages of neural crest migration shows a decreased migration distance upon overexpression (Fig. 4B) or knock down (Fig. 3A, C, and E). However, when these embryos are allowed to develop to later stages, neural crest migration recovers (data not shown), indicating that migration is disrupted but not prevented by loss or gain of Pald. Interpretation of knock down effects is complex: because embryos were electroporated with morpholino at mid-gastrula stages, migration defects (Fig. 3) could be a secondary consequence of earlier effects on neural crest gene expression during specification (Fig. 2). Unfortunately we could not separate the role of Pald in premigratory and migratory neural crest development by timed electroporation as electroporation of Pald MOs later than HH stage 5 had no phenotype (data not shown). Given this is quite an early stage, we presume that Pald is a stable protein that accumulates to sufficient levels for normal development by stage 5. Nevertheless, three observations argue that Pald regulates migration directly. First of all, *Snail2* and *Sox10* expression in neural crest cells recovers by migratory stages although migration is still impaired (Fig. 3). This suggests specification defects are not preventing migration. Second, migration is more severely affected than specification following Pald knock down (compare Figs. 2H and 3F), suggesting these outcomes are independent. Third, following Pald knock down *Cad6b* downregulates on schedule and *RhoB* is expressed normally, suggesting there is not a general block to neural crest development, but that specific regulators of specification and migration are affected. Importantly, temporally normal expression of *Cad6b* and *RhoB* also suggests that Pald targets likely do not include factors that regulate epithelial to mesenchymal transition. Taken together, these results suggest that Pald regulates early migration away from the neural tube, but its function is not critical for emigration and active migration into the periphery.

It is surprising that we observed similar phenotypes upon overexpression and knock down of Pald. One explanation is that providing excess Pald causes it to be mislocalized and/or abnormally sequestered within a cell, removing it from its normal site of action and effectively causing a Pald loss of function phenotype. Another possibility is that a precise level of Pald is necessary to maintain the correct balance of target protein phosphorylation/dephosphorylation necessary for proper function. In other words, target dephosphorylation (absence of Pald, phosphorylated sites unprotected) and target hyperphosphorylation (excess of Pald, sites always phosphorylated) might equally prevent normal target protein activity and thus elicit the same phenotype.

Classification of Paladin as an antiphosphatase

Determining the mechanism by which Pald regulates neural crest development is difficult without knowing its biological activity. While Pald contains two core catalytic protein tyrosine phosphatase (PTP) active site motifs (CX₅R, Fig. 4D; Alonso et al., 2004; Fauman and Saper, 1996; Tonks, 2006), it is missing

additional domains typically associated with tyrosine phosphatase activity, namely the majority of the 280 amino acid extended catalytic domain (Tonks, 2006). For these reasons Pald is frequently cited as an example of a divergent tyrosine phosphatase family member. Alternatively, antiphosphatases contain catalytically inactive PTP domains with altered critical catalytic residues (Alonso et al., 2004). Although the core phosphatase motifs are intact in Paladin, Pald does not exhibit phosphatase activity in vitro (Huang et al., 2009), increasing our suspicion that Pald may instead be an antiphosphatase.

Mutation of a PTP domain by substituting the active site cysteine with a serine inactivates tyrosine phosphatases (Fauman and Saper, 1996) and leads to sustained interactions between a phosphatase and its targets (Flint et al., 1997). We predicted that if Pald is a phosphatase, the cysteine to serine mutation would abolish Paladin function, whereas if Pald is an antiphosphatase the mutation would affect Pald activity minimally, if at all. Overexpression of either wildtype or C285/648S Pald disrupts neural crest migration without any statistically significant difference in the phenotypic outcome (Fig. 4B, C, and E). Furthermore, C285/648S is able to rescue Pald knock down embryos (Fig. 5C and D), indicating the mutation does not abolish Pald activity and implying that Pald is an antiphosphatase. Because the overall proportion of embryos affected by Pald overexpression and C285/648S overexpression is similar with a slight reduction in severity of phenotypes observed (Fig. 4E), and while C285/648S is equally efficient at rescuing Pald knock down with a slight increase in the severity of those affected (Fig. 5D), we conclude that PTP cysteine residues are required for optimal Pald activity.

Because we deduce that Pald is an antiphosphatase, this suggests that regulation of the phosphorylation status of Pald target proteins is required for expression of *Snail2* and *Sox10* during neural crest development. Due to the ability of antiphosphatases to bind to their phosphorylated targets and protect them from dephosphorylation, and the fact that phosphorylation is a known regulator of protein activity, we postulate that Pald acts a signal enhancer to reinforce the activity of phosphorylated target proteins that are necessary for neural crest specification and early steps in migration. The end result is that, although neural crest cells will eventually migrate without Pald activity, expression of Pald prolongs the intensity and duration of regulatory factor activation to promote/accelerate early neural crest development. This hypothesis is supported by the fact that ectopic Pald can only affect neural crest development within the neural crest-forming domain: Pald can only exert its effects when target proteins are already phosphorylated, and Pald itself cannot initiate neural crest formation (Fig. 4B). Further work is needed to identify Pald targets to fully explain the mechanism whereby Pald regulates neural crest development.

A model for Paladin's role in neural crest development

Based on the effects of Pald gain and loss of function, and the consequences of cysteine active site mutations, we propose that Pald is an antiphosphatase. Given that changes in phosphorylation state are essential for proper neural crest migration (Minichiello et al., 1999; Monier-Gavelle and Duband, 1995; Newgreen and Minichiello, 1995), we hypothesize that specific neural crest regulatory proteins are phosphorylated and that this phosphorylation status either positively or negatively affects protein activity during neural crest development depending on the identity of the protein. According to our working model, Pald binds to these phosphorylated proteins, protects their phosphotyrosine residues from dephosphorylation and sustains the activity necessary for proper neural crest gene expression and subsequent migration (Fig. 6A). When Pald phosphatase domain active site cysteines are mutated to serines in C285/648S, the mutant protein does not protect its phosphorylated targets as well as wildtype Pald. This results in less stable phosphorylation and altered

A Model for Paladin's Biological Activity




Fig. 6. A model for Paladin's role in neural crest development. (A) Predicted mechanism of Paladin's biological activity. A Paladin target protein (orange oval) is tyrosine-phosphorylated (dark pink P) during neural crest development. Paladin (blue star) binds to the phosphotyrosine, protecting it from removal by phosphatases (turquoise hexagon) and sustaining target protein activity. (B) In a C285/648S Paladin mutant, we predict that the loss of the critical cysteine reduces the affinity or specificity of mutant Paladin (light blue star) for the target phosphotyrosine, making protection from dephosphorylation less efficient (light pink P). We predict that expression of C285/648S mutant Paladin results in partial dephosphorylation of target protein(s), which we expect would lead to a slight decrease in *Snail2* and *Sox10* as well as the observed mild disruption of neural crest migration and less effective rescue. (C) Paladin knock down results in unprotected target phosphotyrosines, allowing for dephosphorylation by a phosphatase. This alters target protein activity which impedes *Snail2* and *Sox10* expression and disrupts early phases of neural crest migration.

activity of these targets, leading to mild effects on migration and, we predict, gene expression (Fig. 6B). Pald loss of function results in dephosphorylation of Pald targets, which leads to a reduction in both *Snail2* and, to a lesser extent, *Sox10*, as well as disrupted neural crest migration (Fig. 6C). Future identification of Pald targets and examination of their phospho-regulation within premigratory and migratory neural crest cells will shed light on an understudied mechanism to regulate neural crest development.

Acknowledgments

We thank Carol Erickson, Paul Scotting, Andrea Streit, and Lisa Taneyhill for kind gifts of plasmids. Special thanks to Wuming Gong for assistance with statistical analyses. We are grateful to the members of the Gammill Lab and Yasuhiko Kawakami for their input over the course of this project. This work was supported by the National Institute of Dental and Craniofacial Research of the National Institutes of Health award number K22 DE15309 (to LSG) and Ruth L. Kirschstein National Research Service Award number F32 DE019973 (to JRA), and a Minnesota Medical Foundation Research Grant.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.ydbio.2012.08.007>.

References

- Adams, M.S., Gammill, L.S., Bronner-Fraser, M., 2008. Discovery of transcription factors and other candidate regulators of neural crest development. *Dev. Dyn.* 237, 1021–1033.

- Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., Mustelin, T., 2004. Protein tyrosine phosphatases in the human genome. *Cell* 117, 699–711.
- Banerjee, S., Gordon, L., Donn, T.M., Berti, C., Moens, C.B., Burden, S.J., Granato, M., 2011. A novel role for *MuSK* and non-canonical Wnt signaling during segmental neural crest cell migration. *Development* (Cambridge, England) 138, 3287–3296.
- Basch, M., Bronner-Fraser, M., Garcia-Castro, M., 2006. Specification of the neural crest occurs during gastrulation and requires *Pax7*. *Nature* 441, 218–222.
- Betancur, P., Bronner-Fraser, M., Sauka-Spengler, T., 2010. Assembling neural crest regulatory circuits into a gene regulatory network. *Annu. Rev. Cell Dev. Biol.* 26, 581–603.
- Boardman, P.E., Sanz-Ezquerro, J., Overton, I.M., Burt, D.W., Bosch, E., Fong, W.T., Tickle, C., Brown, W.R.A., Wilson, S.A., Hubbard, S.J., 2002. A comprehensive collection of chicken cDNAs. *Curr. Biol.* 12, 1965–1969.
- Brennan, H., Smith, S., Stoker, A., 1999. Phosphotyrosine signalling as a regulator of neural crest cell adhesion and motility. *Cell Motil. Cytoskeleton* 42, 101–113.
- Cheng, Y.-C., Cheung, M., Abu-Elmagd, M.M., Orme, A., Scotting, P.J., 2000. *Chick Sox10*, a transcription factor expressed in both early neural crest cells and central nervous system. *Dev. Brain Res.* 121, 233–241.
- Chizhikov, V.V., Millen, K.J., 2004a. Control of roof plate formation by *Lmx1a* in the developing spinal cord. *Development* (Cambridge, England) 131, 2693–2705.
- Chizhikov, V.V., Millen, K.J., 2004b. Mechanisms of roof plate formation in the vertebrate CNS. *Nat. Rev.* 5, 808–812.
- Collazo, A., Bronner-Fraser, M., Fraser, S.E., 1993. Vital dye labelling of *Xenopus laevis* trunk neural crest reveals multipotency and novel pathways of migration. *Development* (Cambridge, England) 118, 363–376.
- Cui, X., De Vivo, I., Slany, R., Miyamoto, A., Firestein, R., Cleary, M.L., 1998. Association of SET domain and myotubularin-related proteins modulates growth control. *Nat. Genet.* 18, 331–337.
- Duband, J.L., 2006. Neural crest delamination and migration: integrating regulations of cell interactions, locomotion, survival and fate. *Adv. Exp. Med. Biol.* 589, 45–77.
- Fauman, E.B., Saper, M.A., 1996. Structure and function of the protein tyrosine phosphatases. *Trends Biochem. Sci.* 21, 413–417.
- Firulli, A.B., Conway, S.J., 2008. Phosphoregulation of *Twist1* provides a mechanism of cell fate control. *Curr. Med. Chem.* 15, 2641–2647.
- Flint, A.J., Tiganis, T., Barford, D., Tonks, N.K., 1997. Development of “substrate-trapping” mutants to identify physiological substrates of protein tyrosine phosphatases. *Proc. Nat. Acad. Sci. USA* 94, 1680–1685.
- Fuse, N., Hirose, S., Hayashi, S., 1996. Determination of wing cell fate by the *escargot* and *snail* genes in *Drosophila*. *Development* (Cambridge, England) 122, 1059–1067.
- Gammill, L.S., Bronner-Fraser, M., 2002. Genomic analysis of neural crest induction. *Development* (Cambridge, England) 129, 5731–5741.
- Gammill, L.S., Krull, C.E., 2011. Embryological and genetic manipulation of chick development. *Methods Mol. Biol.* 770, 119–137.
- Gingras, M.C., Zhang, Y.L., Kharitidi, D., Barr, A.J., Knapp, S., Tremblay, M.L., Pause, A., 2009. HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain. *PLoS One* 4, e5105.
- Glavic, A., Silva, F., Aybar, M.J., Bastidas, F., Mayor, R., 2004. Interplay between Notch signaling and the homeoprotein *Xiro1* is required for neural crest induction in *Xenopus* embryos. *Development* (Cambridge, England) 131, 347–359.
- Guan, K.L., Dixon, J.E., 1991. Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. *J. Biol. Chem.* 266, 17026–17030.
- Hamburger, V., Hamilton, H.L., 1951. A series of normal stages in the development of the chick embryo. *J. Morphol.* 88, 231–272.
- Heckman, K.L., Pease, L.R., 2007. Gene splicing and mutagenesis by PCR-driven overlap extension. *Nat. Protocols* 2, 924–932.
- Huang, S.M., Hancock, M.K., Pitman, J.L., Orth, A.P., Gekakis, N., 2009. Negative regulators of insulin signaling revealed in a genome-wide functional screen. *PLoS One* 4, e6871.
- Jin, J., Wu, L.-J., Jun, J., Cheng, X., Xu, H., Andrews, N.C., Clapham, D.E., 2012. The channel kinase, *TRPM7*, is required for early embryonic development. *Proc. Nat. Acad. Sci. USA* 109, E225–E233.
- Kos, R., Reedy, M.V., Johnson, R.L., Erickson, C.A., 2001. The winged-helix transcription factor *FoxD3* is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos. *Development* (Cambridge, England) 128, 1467–1479.
- Latta, E.J., Golding, J.P., 2012. Regulation of PP2A activity by *Mid1* controls cranial neural crest speed and gangliogenesis. *Mech. Dev.*
- LeDouarin, N., Kalchauer, C., 1999. *The Neural Crest*. Cambridge University Press, Cambridge, UK.
- Linker, C., Bronner-Fraser, M., Mayor, R., 2000. Relationship between gene expression domains of *Xsnail*, *Xslug*, and *Xtwist* and cell movement in the prospective neural crest of *Xenopus*. *Dev. Biol.* 224, 215–225.
- Liu, J.P., Jessell, T.M., 1998. A role for *rhoB* in the delamination of neural crest cells from the dorsal neural tube. *Development* (Cambridge, England) 125, 5055–5067.
- Milarski, K.L., Zhu, G., Pearl, C.G., McNamara, D.J., Dobrusin, E.M., MacLean, D., Thieme-Seifler, A., Zhang, Z.Y., Sawyer, T., Decker, S.J., et al., 1993. Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B. *J. Biol. Chem.* 268, 23634–23639.
- Minichiello, J., Ben-Yacov, A., Hearn, C.J., Needham, B., Newgreen, D.F., 1999. Induction of epithelio-mesenchymal transformation of quail embryonic neural cells by inhibition of atypical protein kinase-C. *Cell Tissue Res.* 295, 195–206.
- Monier-Gavelle, F., Duband, J.L., 1995. Control of N-cadherin-mediated intercellular adhesion in migrating neural crest cells in vitro. *J. Cell Sci.* 108 (Pt 12), 3839–3853.
- Moulton, J.D., Yan, Y.L., 2008. Using morpholinos to control gene expression. *Curr. Protocols Mol. Biol.* 83, 26.8.1–26.8.29.
- Murphy, D.A., Diaz, B.A., Bromann, P.A., Tsai, J.H., Kawakami, Y., Maurer, J., Stewart, R.A., Izpisua-Belmonte, J.C., Courtneidge, S.A., 2011. A *Src-Tks5* pathway is required for neural crest cell migration during embryonic development. *PLoS One* 6, e22499.
- Nagase, T., Ishikawa, K., Kikuno, R., Hirose, M., Nomura, N., Ohara, O., 1999. Prediction of the coding sequences of unidentified human genes. XV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. *DNA Res.* 6, 337–345.
- Nakamura, T., Gulick, J., Colbert, M.C., Robbins, J., 2009. Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development. *Proc. Nat. Acad. Sci. USA* 106, 11270–11275.
- Newgreen, D.F., Minichiello, J., 1995. Control of epitheliomesenchymal transformation. I. Events in the onset of neural crest cell migration are separable and inducible by protein kinase inhibitors. *Dev. Biol.* 170, 91–101.
- Ossipova, O., Sokol, S.Y., 2011. Neural crest specification by noncanonical Wnt signaling and *PAR-1*. *Development* (Cambridge, England) 138, 5441–5450.
- R Development Core Team, 2011. R: A Language and Environment for Statistical Computing. <http://www.R-project.org>.
- Sato, T., Sasaki, N., Sasaki, Y., 2005. Neural crest determination by co-activation of *Pax3* and *Zic1* genes in *Xenopus* ectoderm. *Development* (Cambridge, England) 132, 2355–2363.
- Sauka-Spengler, T., Bronner-Fraser, M., 2008. A gene regulatory network orchestrates neural crest formation. *Nat. Rev. Mol. Cell Biol.* 9, 557–568.
- Sefton, B.M., Shenolikar, S., 2001. Overview of protein phosphorylation. *Curr. Protocols Protein Sci.* 13.1.1–13.1.5.
- Selleck, M.A., Bronner-Fraser, M., 1995. Origins of the avian neural crest: the role of neural plate-epidermal interactions. *Development* (Cambridge, England) 121, 525–538.
- Stewart, R.A., Sanda, T., Widlund, H.R., Zhu, S., Swanson, K.D., Hurley, A.D., Bentires-Alj, M., Fisher, D.E., Kontaridis, M.I., Look, A.T., Neel, B.G., 2010. Phosphatase-dependent and -independent functions of *Shp2* in neural crest cells underlie LEOPARD syndrome pathogenesis. *Dev. Cell* 18, 750–762.
- Swartz, M.E., Eberhart, J., Pasquale, E.B., Krull, C.E., 2001. *EphA4/ephrin-A5* interactions in muscle precursor cell migration in the avian forelimb. *Development* (Cambridge, England) 128, 4669–4680.
- Taneyhill, L.A., Coles, E.G., Bronner-Fraser, M., 2007. *Snail2* directly represses *cadherin6B* during epithelial-to-mesenchymal transitions of the neural crest. *Development* (Cambridge, England) 134, 1481–1490.
- Tonks, N.K., 2006. Protein tyrosine phosphatases: from genes, to function, to disease. *Nat. Rev. Mol. Cell Biol.* 7, 833–846.
- Tribulo, C., Aybar, M.J., Nguyen, V.H., Mullins, M.C., Mayor, R., 2003. Regulation of *Msx* genes by a *Bmp* gradient is essential for neural crest specification. *Development* (Cambridge, England) 130, 6441–6452.
- Turner, D.L., Weintraub, H., 1994. Expression of *achaete-scute* homolog 3 in *Xenopus* embryos converts ectodermal cells to a neural fate. *Genes Dev.* 8, 1434–1447.
- Uwanogho, D., Rex, M., Cartwright, E.J., Pearl, G., Healy, C., Scotting, P.J., Sharpe, P.T., 1995. Embryonic expression of the chicken *Sox2*, *Sox3* and *Sox11* genes suggests an interactive role in neuronal development. *Mech. Dev.* 49, 23–36.
- Vernon, A.E., LaBonne, C., 2006. *Slug* stability is dynamically regulated during neural crest development by the F-box protein *Ppa*. *Development* (Cambridge, England) 133, 3359–3370.
- Wettstein, D.A., Turner, D.L., Kintner, C., 1997. The *Xenopus* homolog of *Drosophila* *Suppressor of Hairless* mediates Notch signaling during primary neurogenesis. *Development* (Cambridge, England) 124, 693–702.
- Wilkinson, D., 1992. Whole mount *in situ* hybridization of vertebrate embryos. In: Wilkinson, D. (Ed.), *In Situ Hybridization: A Practical Approach*. Oxford University Press, Oxford, pp. 75–83.
- Wishart, M.J., Dixon, J.E., 1998. Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. *Trends Biochem. Sci.* 23, 301–306.
- Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., Gunduz, M., Hung, M.C., 2004. Dual regulation of *Snail* by GSK-3 β -mediated phosphorylation in control of epithelial-mesenchymal transition. *Nat. Cell Biol.* 6, 931–940.